Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWRFree Report) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $90.00 price target on the biotechnology company’s stock.

Other research analysts also recently issued reports about the stock. Citigroup lifted their target price on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the stock a neutral rating in a research note on Wednesday. Royal Bank of Canada reiterated an outperform rating and issued a $50.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday. StockNews.com cut shares of Arrowhead Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, November 22nd. Morgan Stanley lifted their price target on shares of Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the company an equal weight rating in a report on Wednesday. Finally, Bank of America lifted their price target on shares of Arrowhead Pharmaceuticals from $29.00 to $37.00 and gave the company a buy rating in a report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of $51.25.

Read Our Latest Stock Analysis on ARWR

Arrowhead Pharmaceuticals Stock Down 2.5 %

Shares of NASDAQ ARWR opened at $30.85 on Thursday. Arrowhead Pharmaceuticals has a 52 week low of $20.67 and a 52 week high of $42.48. The firm’s fifty day moving average is $31.20 and its 200 day moving average is $29.10. The company has a market cap of $3.31 billion, a price-to-earnings ratio of -11.10 and a beta of 0.78.

Arrowhead Pharmaceuticals (NASDAQ:ARWRGet Free Report) last issued its earnings results on Tuesday, February 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.46). Arrowhead Pharmaceuticals had a negative return on equity of 78.50% and a negative net margin of 163.32%. The firm had revenue of $3.55 million during the quarter, compared to analysts’ expectations of $35.60 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. The firm’s quarterly revenue was down 94.3% compared to the same quarter last year. Equities research analysts anticipate that Arrowhead Pharmaceuticals will post -3.27 earnings per share for the current year.

Insider Activity

In other news, insider Martin Javier San sold 19,700 shares of the business’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $28.80, for a total transaction of $567,360.00. Following the sale, the insider now owns 131,800 shares in the company, valued at approximately $3,795,840. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Martin Javier San sold 19,700 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $28.80, for a total value of $567,360.00. Following the completion of the transaction, the insider now owns 131,800 shares of the company’s stock, valued at approximately $3,795,840. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Christopher Richard Anzalone sold 57,499 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $32.35, for a total value of $1,860,092.65. Following the completion of the transaction, the chief executive officer now directly owns 3,715,048 shares of the company’s stock, valued at approximately $120,181,802.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 196,139 shares of company stock worth $6,471,839. Corporate insiders own 4.50% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently modified their holdings of ARWR. Captrust Financial Advisors raised its position in Arrowhead Pharmaceuticals by 22.4% in the 2nd quarter. Captrust Financial Advisors now owns 1,201 shares of the biotechnology company’s stock worth $42,000 after buying an additional 220 shares during the last quarter. Advisors Asset Management Inc. raised its position in Arrowhead Pharmaceuticals by 94.6% in the 1st quarter. Advisors Asset Management Inc. now owns 720 shares of the biotechnology company’s stock worth $33,000 after buying an additional 350 shares during the last quarter. Thrivent Financial for Lutherans raised its position in Arrowhead Pharmaceuticals by 1.4% in the 1st quarter. Thrivent Financial for Lutherans now owns 28,584 shares of the biotechnology company’s stock worth $726,000 after buying an additional 390 shares during the last quarter. Strs Ohio raised its position in Arrowhead Pharmaceuticals by 1.5% in the 2nd quarter. Strs Ohio now owns 26,600 shares of the biotechnology company’s stock worth $948,000 after buying an additional 400 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in Arrowhead Pharmaceuticals by 1.6% in the 2nd quarter. ProShare Advisors LLC now owns 26,496 shares of the biotechnology company’s stock worth $945,000 after buying an additional 428 shares during the last quarter. Hedge funds and other institutional investors own 65.98% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

See Also

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.